PRN Meeting: April 16, 2024 Jointly provided by the Medical Society of the State of New York, at a Zoom webinar, 7:00 p.m. to 9:00 p.m (EST).

Target Audience:

Physicians, Nurse Practitioners, and Physician Assistants caring for people at risk for, or infected with HIV and/or viral hepatitis.

Course Director: James F. Braun, DO, President & Program Planner, Physicians' Research Network

Moderator: Joseph P. McGowan, MD, FACP, FIDSA, Professor, Inst. of Health System Science, Feinstein Inst. for Medical Research, Zucker School of Medicine, Hofstra/Northwell

Guest Speakers and Presentations:

GLP-1 RA and SGLT2i: New Treatment Strategies for Diabetes and Obesity in the Context of HIV

Todd T. Brown, MD, PhD

Professor of Medicine and Epidemiology
Division of Endocrinology, Diabetes, and Metabolism
Johns Hopkins University, Baltimore, MD

At the completion of this educational activity learners will:
1. To describe how GLP-1 receptor agonists and SGLT2 inhibitors work
2. To list the risks and benefits of GLP-1 receptor agonists and SGLT2 inhibitors and where they fit in for the treatment of diabetes.
3. To understand the impact of GLP-1 receptor agonists for the treatment of obesity and be familiar with unanswered questions about their long-term safety and efficacy
4. To understand what is known about these medications in people with HIV.

A Closer Look at HIV and Antibody-Based Interventions for Prevention, Treatment, and Cure

Thomas J. Hope, PhD

Professor, Departments of Cell and Molecular Biology, Obstetrics and Gynecology, Biomedical Engineering
Feinberg School of Medicine
Northwestern University, Chicago, IL

At the completion of this educational activity learners will:
1. Appreciate the focal nature of HIV infection and tissue reservoirs.
2. Increase understanding of the virus and its likely ongoing expression during periods of supposed latency
3. Be aware of the complexities of antibody distribution and cycling in the context of human anatomy and physiology.
4. Gain insights into the advantages and disadvantages of utilizing broadly neutralizing antibodies for HIV prevention, treatment, and cure.

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing Medical Education for physicians.

The Medical Society of the State of New York designates this live activity for a maximum 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statements:

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun (Course Director/Planner) has no relevant financial relationships to disclose.
- Dr. Joseph P. McGowan (Moderator) has no relevant financial relationships to disclose.
- Dr. Todd T. Brown (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or
services that may be presented in this CME activity: Consultant to Merck, ViiV and Janssen. Dr. Brown will support his presentation and clinical
recommendations with the best available evidence from the medical literature, and will submit his slides in advance for adequate peer review. All relevant financial
relationships have been mitigated.
- Dr. Thomas J. Hope (Presenter) has no relevant financial relationships to disclose. Dr. Hope will submit his slides in advance for adequate peer review and will support his presentation and clinical recommendations with the best available evidence from the medical literature.

Financial Support:

This PRN CME activity is funded in part by unrestricted educational grants from Gilead Sciences and ViiV Healthcare.